Clinical Trial Update: GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating GRN1005 alone or with trastuzumab in breast cancer patients with brain metastases has completed (status: COMPLETED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• GRN1005
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Angiochem Inc | Conditions: Breast Cancer, Brain Metastases | Phase 2 | Status: COMPLETED